ArticleApplied and environmental microbiology2025
Tracking poliovirus through wastewater: environmental surveillance insights from Haïti (2020-2023).
Article in Applied and environmental microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Environmental surveillance (ES) for poliovirus is a critical component of global eradication efforts, enabling the detection of virus circulation in communities, even in the absence of acute flaccid paralysis (AFP) cases. To monitor poliovirus circulation in a high-risk setting, ES was established in 2016 in Haïti in two cities (Port-au-Prince and Gonaïves) and expanded to five cities, adding Saint Marc, Cap Haïtien, and Port-de-Paix by 2023. Wastewater samples were collected monthly from 13 sites in urban areas and processed at CDC-Atlanta using the concentration and filtration elution (CaFÉ) method developed to concentrate enteroviruses, including polioviruses. Virus isolation was performed using poliovirus-sensitive (L20B) cells and enterovirus-sensitive (RD) cells, followed by molecular detection screening via real-time reverse transcription PCR designed for enterovirus and poliovirus typing. Between 2020 and 2023, sporadic Sabin-like poliovirus vaccine strains of serotypes 1 and 3 were detected, and no wild poliovirus (WPV) or vaccine-derived poliovirus (VDPV) was identified. The overall enterovirus detection rates ranged from 36% to 91% in 2020, 12% to 58% in 2021, 16% to 60% in 2022, and 27% to 73% in 2023, with some detection rates at some sites much lower than the optimal 50% target for global ES sites. Based on the lower detection rate, used as the main quality indicator for optimal ES, two sampling sites were discontinued in 2023 (one in Saint Marc and one in Cap Haïtien). The findings underscore the importance of high-performing ES in high-risk regions to augment AFP surveillance and serve as an early warning indicator of poliovirus circulation.IMPORTANCEPoliovirus environmental surveillance (ES) is a critical tool for detecting virus circulation before symptomatic cases of acute flaccid paralysis occur, especially in areas with inadequate surveillance. Haïti, a high-risk country for poliovirus transmission, faced numerous challenges from 2020 to 2023 that impacted ES operations, including political instability, humanitarian crisis, and site closures. This study provides a comprehensive evaluation of ES performance during that period, offering insights into surveillance resilience and sustainability in low-resource settings. The findings are timely and relevant, particularly in the context of the recent circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in Europe and Africa, and contribute to optimizing ES strategies globally to support polio eradication efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.